Chimerix (United States)

Recent papers from Chimerix (United States)

1. Urine Molecular Fingerprinting: exploratory study of a promising technology for detecting cancer and nonneoplastic disease in dogsAmerican Journal of Veterinary Research · 2026
2. The nucleoside analog CMX521 inhibits coronavirus RNA-dependent RNA polymerase via a two-pronged mechanismJournal of Biological Chemistry · 2026
3. Preclinical efficacy and mechanism of action of dordaviprone in H3 K27M-mutant diffuse gliomaNeuro-Oncology Pediatrics · 2026
4. Developability engineering of scFvs enables robust CAR function under transient mRNA expressionScientific Reports · 2026
5. Liquid biopsy technologies offer new insights and approaches for canine cancer detection and managementJournal of the American Veterinary Medical Association · 2026
6. Integrated Phenotypic and Transcriptomic Profiling Positions ONC212 as a Lead Imipridone in Androgen-Independent Prostate Cancer ModelsInternational Journal of Molecular Sciences · 2026
7. ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastomaNeuro-Oncology · 2026
8. MODL-02. ONC206 inhibits tumor growth and is a potential novel therapeutic strategy for refractory medulloblastomaNeuro-Oncology Pediatrics · 2025
9. Lack of resistance development during brincidofovir therapy in animal models of orthopoxvirus infectionAntiviral Research · 2026
10. Abstract PS4-07-19: An agonist of mitochondrial CLPP, ONC206, overcomes mitochondrial dependencies and abates chemoresistance in triple negative breast cancerClinical Cancer Research · 2026
11. ONC201 for chemoprevention of colorectal cancer.Journal of Clinical Oncology · 2026
12. A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of DordaviproneThe Journal of Clinical Pharmacology · 2025
13. ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma2025
14. Effect of Severe Renal Impairment on Dordaviprone (ONC201) PharmacokineticsDrugs in R&D · 2025
15. Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic ModelingCPT Pharmacometrics & Systems Pharmacology · 2025
16. The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspectiveNeuro-Oncology · 2025
17. Prognostic Features of Recurrent Midline and H3 K27M-Mutant GliomaCancers · 2025
18. Investigating the Effects of ONC206 Alone and in Combination with Cisplatin on Ovarian Cancer Cell ModelsCurrent Issues in Molecular Biology · 2025
19. A phase 1, randomized, crossover trial to assess the effect of itraconazole on the pharmacokinetics of dordaviprone in healthy adultsBritish Journal of Clinical Pharmacology · 2025
20. A Phase 1 Study to Evaluate the Absorption, Metabolism, and Disposition of Dordaviprone in Healthy Adult ParticipantsClinical Pharmacology in Drug Development · 2025